171 related articles for article (PubMed ID: 38830503)
1. THPdb2: compilation of FDA approved therapeutic peptides and proteins.
Jain S; Gupta S; Patiyal S; Raghava GPS
Drug Discov Today; 2024 Jun; 29(7):104047. PubMed ID: 38830503
[TBL] [Abstract][Full Text] [Related]
2. THPdb: Database of FDA-approved peptide and protein therapeutics.
Usmani SS; Bedi G; Samuel JS; Singh S; Kalra S; Kumar P; Ahuja AA; Sharma M; Gautam A; Raghava GPS
PLoS One; 2017; 12(7):e0181748. PubMed ID: 28759605
[TBL] [Abstract][Full Text] [Related]
3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
4. U.S. FDA Approved Drugs from 2015-June 2020: A Perspective.
Bhutani P; Joshi G; Raja N; Bachhav N; Rajanna PK; Bhutani H; Paul AT; Kumar R
J Med Chem; 2021 Mar; 64(5):2339-2381. PubMed ID: 33617716
[TBL] [Abstract][Full Text] [Related]
5. The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2024 Jan; 29(3):. PubMed ID: 38338330
[TBL] [Abstract][Full Text] [Related]
6. 'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.
Gaylis N; Both C; Lemke L; von Richter O; Yamauchi P
Adv Ther; 2024 May; 41(5):1795-1814. PubMed ID: 38514505
[TBL] [Abstract][Full Text] [Related]
7. The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770706
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
[TBL] [Abstract][Full Text] [Related]
9. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
[TBL] [Abstract][Full Text] [Related]
10. Fresh Baked: An Overview of Newly FDA-Approved Drugs for Dermatological Usage.
Sikder B; Sil A
Indian J Dermatol; 2023; 68(6):707-720. PubMed ID: 38371570
[TBL] [Abstract][Full Text] [Related]
11. Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018-2022).
Ali S; Zhou J
Eur J Med Chem; 2023 Aug; 256():115476. PubMed ID: 37207534
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of genotoxicity testing of FDA approved large molecule therapeutics.
Sawant SG; Fielden MR; Black KA
Regul Toxicol Pharmacol; 2014 Oct; 70(1):87-97. PubMed ID: 24932799
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody: the corner stone of modern biotherapeutics.
Xia ZN; Cai XT; Cao P
Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
[TBL] [Abstract][Full Text] [Related]
14. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2020 Feb; 25(3):. PubMed ID: 32050446
[TBL] [Abstract][Full Text] [Related]
15. The U.S. FDA approved cardiovascular drugs from 2011 to 2023: A medicinal chemistry perspective.
Jiang Y; Liu P; Qiu Z; Zhou M; Cheng M; Yang T
Eur J Med Chem; 2024 Jun; 275():116593. PubMed ID: 38889609
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
Rivera VM
Neurol Ther; 2019 Dec; 8(2):177-184. PubMed ID: 31313222
[TBL] [Abstract][Full Text] [Related]
17. DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Wishart DS; Knox C; Guo AC; Cheng D; Shrivastava S; Tzur D; Gautam B; Hassanali M
Nucleic Acids Res; 2008 Jan; 36(Database issue):D901-6. PubMed ID: 18048412
[TBL] [Abstract][Full Text] [Related]
18. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges.
Chapman K; Adjei A; Baldrick P; da Silva A; De Smet K; DiCicco R; Hong SS; Jones D; Leach MW; McBlane J; Ragan I; Reddy P; Stewart DI; Suitters A; Sims J
MAbs; 2016; 8(3):427-35. PubMed ID: 26854177
[TBL] [Abstract][Full Text] [Related]
19. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
